Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GUCY2C CAR-T Therapy in Digestive System Tumors
NCT04780529Phase 2Not yet recruiting
- Sponsor
- Innovative Cellular Therapeutics
- Start
- Mar 2021
- Primary completion
- Apr 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in colorectal cancer (CRC), gastric cancer (GC), liver cancer and 3 more, sponsored by Innovative Cellular Therapeutics. Primary endpoint: Number of participants with CAR-T treatment-related adverse events at 24 months. Planned start Mar 2021; status: not yet recruiting.
02
Conditions
colorectal cancer (CRC)gastric cancer (GC)liver cancerpancreatic cancer (PC)esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT04780529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04780529.